With base substitution mutations, only a single nucleotide within a gene sequence is changed, so only one codon is affected (Figure 1). Insertions and deletions are two other types of mutations ...

The Phase III trial, which enrolled 1,074 patients, pitted the combination of Rybrevant and Lazcluze against AstraZeneca’s Tagrisso (osimertinib), which is considered the SOC, a ...

Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s (NYSE: JNJ) Darzalex (daratumumab) for the treatment of adult patients with ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.